Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:SQZ

SQZ BIOTECHNOLOGIES CO

3.35Down -0.03 (-0.8876 %)as of 4:10:00pm ET 05/24/2022

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

    Business Wire – 6:45 AM ET 05/18/2022

    Average Processing Time Per Batch Less Than 6 Hours – a 55% Reduction with Comparable or Improved Product Metrics First Clinical Use Planned for SQZ® TACs in Celiac Disease with IND Submission Anticipated in 1H 2023 Preclinical Data on Hematopoietic Stem Cell Engineering and Planned Commercial Research-Use-Only System Presented at ASGCT 2022 Support Potential for Broad Future Point-of-Care Manu...
  2. Show article details.

    BRIEF-SQZ Biotechnologies Reports First Quarter 2022 Results

    Reuters – 4:58 PM ET 05/10/2022

    SQZ Biotechnologies Co (SQZ): * SQZ BIOTECHNOLOGIES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND RECENT PORTFOLIO UPDATES. * QTRLY LOSS PER SHARE $0.75. * Q1 EARNINGS PER SHARE VIEW $-0.71 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
  3. Show article details.

    SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates

    Business Wire – 4:50 PM ET 05/10/2022

    WATERTOWN, Mass. “Our year is off to an exciting start with the FDA IND clearance to initiate clinical trials of our eAPCs – our multifunctional mRNA-based investigational cell therapy that targets solid tumors by engineering multiple T cell signals simultaneously,” said Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies.
  4. Show article details.

    SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022

    Business Wire – 4:45 PM ET 05/05/2022

    SQZ Biotechnologies (SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the company will host a live R&D investor event with optional virtual participation on Thursday, May 19, 2022, from 4:05 - 5:30 p.m. ET.
  5. Show article details.

    SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research

    Business Wire – 6:45 AM ET 05/05/2022

    SQZ’s Point-of-Care Manufacturing Platform Shows Promising Results with Ability to Produce Cell Therapies at Scale in Under 10 Hours Co-Development of Research-Use-Only System with STEMCELL Technologies to Help Drive Cell Therapy Innovation by the Broader Scientific Community Presentations on the POC Manufacturing Platform, Research Scale System and Hematopoietic Stem Cell Engineering Preclinic...
  6. Show article details.

    SQZ Biotechnologies to Present at Upcoming Investor Conferences

    Business Wire – 4:30 PM ET 05/03/2022

    SQZ Biotechnologies (SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies (SQZ), will present at the Bank of America Securities 2022 Healthcare Conference on May 10, in Las Vegas, Nevada and at the H.C. Wainwright Global Investment Conference on May 25, in Miami, F...
  7. Show article details.

    74 Biggest Movers From Yesterday

    Benzinga – 5:19 AM ET 04/29/2022

    74 Biggest Movers From Yesterday
  8. Show article details.

    48 Stocks Moving In Thursday's Mid-Day Session

    Benzinga – 12:05 PM ET 04/28/2022

    48 Stocks Moving In Thursday's Mid-Day Session
  9. Show article details.

    Mid-Morning Market Update: Markets Open Higher; US Economy Contracts 1.4% In Q1

    Benzinga – 10:07 AM ET 04/28/2022

    U.S. stocks traded higher this morning with the Dow Jones gaining 300 points on Thursday. Following the market opening Thursday, the Dow traded up 0.45% to 33,450.24 while the NASDAQ rose 0.88% to 12,598.27. The S&P also rose, gaining, 0.84% to 4,219.18. Also check this: Executives Buy Around $65M Of 3 Stocks Leading and Lagging Sectors Communication services shares rose by 1.9% on Thursday.
  10. Show article details.

    The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

    Benzinga – 8:52 AM ET 04/28/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: Moderna Inc  submitted a request for FDA emergency use authorization  for its COVID-19 vaccine in children 6 months to under 6 years of age. The requests are based on a 25 μg two-dose primary series of mRNA-1273. The EUA submission for children ages 6 months to under 6 years will be complete next week.
  11. Show article details.

    28 Stocks Moving in Thursday's Pre-Market Session

    Benzinga – 6:30 AM ET 04/28/2022

    Don't forget to check out our premarket coverage here .
  12. Show article details.

    BRIEF-SQZ Biotechnologies Receives FDA Fast Track Designation For Its Lead Cell Therapy Candidate For The Treatment Of HPV16+ Tumors

    Reuters – 5:54 PM ET 04/27/2022

    SQZ Biotechnologies Co (SQZ): * SQZ BIOTECHNOLOGIES RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LEAD CELL THERAPY CANDIDATE FOR THE TREATMENT OF HPV16+ TUMORS Source text for Eikon: Further company coverage:
  13. Show article details.

    SQZ Biotechnologies Receives FDA Fast Track Designation for SQZ-PBMC-HPV for the Treatment of HPV16+ Tumors

    Benzinga – 5:19 PM ET 04/27/2022

    SQZ Biotechnologies  received Fast Track Designation from he U.S. Food and Drug Administration for its lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. SQZ-PBMC-HPV-101 is currently being investigated in the Phase 1/2 clinical study.
  14. Show article details.

    SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

    Business Wire – 4:45 PM ET 04/27/2022

    Designation Creates Potential to Bring Important New Therapy to Patients Earlier SQZ Biotechnologies (SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic...
  15. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 2:41 PM ET 04/27/2022

      Wednesday's session saw 784 companies set new 52-week lows. The following stocks set new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.
  16. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 1:44 PM ET 04/26/2022

      During Tuesday, 581 stocks hit new 52-week lows. Meta Platforms was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science. During Tuesday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.
  17. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 1:54 PM ET 04/21/2022

      On Thursday, 236 companies hit new 52-week lows. Stocks that set new 52-week lows are as follows: Be sure to monitor Benzinga for the news traders need!
  18. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:14 PM ET 04/20/2022

      On Wednesday, 160 companies hit new 52-week lows. The following stocks set new 52-week lows on Wednesday: Be sure to monitor Benzinga for the news traders need!
  19. Show article details.

    BRIEF-SQZ Biotechnologies Presents New EAPC Preclinical Data

    Reuters – 7:38 AM ET 04/11/2022

    SQZ Biotechnologies Co (SQZ): * SQZ BIOTECHNOLOGIES PRESENTS NEW EAPC PRECLINICAL DATA DEMONSTRATING THAT MULTIPLEXED MRNA ENGINEERING OF IMMUNE CELLS INCREASES KILLER T CELL ACTIVITY IN VIVO Source text for Eikon: Further company coverage:
  20. Show article details.

    SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

    Business Wire – 6:45 AM ET 04/11/2022

    SQZ® eAPC Platform Demonstrates that mRNA-based Expression of Co-Stimulatory CD86 and Membrane-bound IL-2 and IL-12 Dramatically Increases Antigen-Specific CD8 T Cell Activity. T Cell Responses Shown Across Multiple Antigens In Vitro and In Vivo Using mRNAs that Encode Infectious Disease or Tumor-Related Antigens, including HPV and KRAS.
Page:

Today's and Upcoming Events

  • Aug
    02

    SQZ to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    10

    SQZ announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.